Alkermes.
company
- Reports this week
- 1
- Active events
- 2
- Connections
- 69
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Alkermes expanded access with three large Medicare Part D plans.Some support2 reports
-
Norges Bank purchased a new stake in Alkermes and disclosed financial information to the SEC.Some support1 report
-
MarketBeat is tracking analyst ratings and price targets for Alkermes stock, involving Royal Bank of Canada.Some support5 reports
-
Alkermes is developing a generic equivalent of a brand product and seeking market entry for generic drugs in partnership with Granules India Limited.Some support1 report
-
Alkermes filed transaction disclosures with the SEC on July 1, 2026.Some support3 reports
-
Bank of America and Royal Bank of Canada raised price targets and ratings for Alkermes on June 17, 2026.Some support1 report
-
The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.Some support1 report
-
Director Christopher Wright sold shares of Alkermes stock, with the transaction disclosed in a legal filing with the SEC.Some support3 reports
-
FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.Some support3 reports2 developments inside
-
Alkermes is integrating Avadel into its operations while discussing differentiation within the orexin agonist class.Some support1 report
-
Alkermes stock was listed on the Nasdaq exchange on June 6, 2026.Some support3 reports
-
Alkermes plc, headquartered in Ireland, plans to present findings at SLEEP 2025 in Seattle.Some support1 report
-
Brian P. McKeon was appointed to the Board of Directors of National Veterinary Associates.Some support1 report
-
Analysts set price targets for Alkermes stock on July 14, 2025.Some support1 report
-
Alkermes (Q30283646) is being analyzed by Wall Street regarding how key metrics influenced its top- and bottom-line performance.Some support1 report
-
Alkermes plc, a biopharmaceutical company, is based in Ireland.Well supported4 reports
-
Alkermes plans to present research results at the World Sleep Congress in Singapore.Some support2 reports
-
Alkermes and CSL Limited are noted as stocks in the Medical-Biomedical and Genetics sector as of July 1, 2025.Speculative1 report
-
Alkermes and Takeda are developing orexin-related therapies and plan to present detailed data at a meeting on July 21, 2025.Some support1 report
-
Alkermes reported its financial results from Dublin in July 2025.Some support2 reports
-
Alkermes underperformed the market so far this year as of July 29, 2025.Some support1 report
-
Xoma is acquiring Mural Oncology, a company that was previously spun out of Alkermes.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Alkermes this week
News at the entities that move Alkermes most-
SEC StructuralDirector Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Moves Alkermes
-
representative TransactionalA representative is facing pressure to satisfy constituents' expectations.Moves Alkermes
-
Jackson StructuralJackson defeated Maxwell in a reelection bid across Kankakee, Cook, and Will Counties.Moves Alkermes
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Alkermes
-
European Commission StructuralRomania is handing over the Central European Initiative (CEI) presidency, with Ukraine set to assume the role in 2027.Moves Alkermes
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada cut its target price for aTyr Pharma, which was reported by Benzinga.Moves Alkermes
Connections
The 24 strongest of 69, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Alkermes is subject to formal regulatory oversight and disclosure requirements by the SEC.
-
representative Transactional
Representative purchased shares of Alkermes.
-
Jackson Structural
Jackson serves as the CEO of Alkermes.
-
FDA Structural
Alkermes operates within the regulatory framework of the FDA, seeking designation and approval for its products.
-
European Commission Structural
Alkermes is currently engaged in a regulatory process with the European Commission regarding the designation of its product alixorexton for narcolepsy.
-
Eli Lilly and Company Operational
Alkermes and Eli Lilly compete directly for market share in the narcolepsy drug segment.
-
Mural Structural
Mural was historically spun out of Alkermes, establishing a former parent-subsidiary relationship.
-
Royal Bank of Canada Mentioned together
RBC provides consistent analyst ratings, research reports, and institutional holdings updates regarding Alkermes stock.
Show all 24 connections
-
executive Structural
Alkermes's structure involves leadership transitions among its executives following performance reviews.
-
Bank of America Mentioned together
Bank of America provides financial analysis, including price targets and ratings, for Alkermes.
-
Granules India Limited Operational
The companies are actively developing generic equivalents of brand products, indicating market competition.
-
Truist Financial Transactional
Truist Financial provides stock coverage and rating upgrades for Alkermes.
-
Gil Cisneros Transactional
Gil Cisneros purchased shares of Alkermes.
-
Dublin Shared context
Alkermes operates and reports financial results from its location in Dublin.
-
MarketBeat Mentioned together
MarketBeat provides and tracks analyst recommendations and price targets for Alkermes.
-
Norges Bank Transactional
Norges Bank purchased a new stake in Alkermes as of July 25, 2026.
-
Maastricht Shared context
Alkermes is scheduled to present research in Maastricht.
-
Ireland Shared context
Alkermes is headquartered and based in Ireland.
-
Christopher Wright Transactional
Director Christopher Wright sold shares of Alkermes stock.
-
Needham Mentioned together
Needham is observed reporting on Alkermes' regulatory activities, specifically concerning insider sales disclosures.
-
Massachusetts Shared context
Alkermes maintains its corporate office and R&D center within the state of Massachusetts.
-
Nasdaq Shared context
Alkermes is a company whose stock is listed and traded on the Nasdaq exchange.
-
Ohio Shared context
Alkermes maintains a manufacturing facility located within the state of Ohio.
-
Netherlands Shared context
Alkermes operates within the geographical context of the Netherlands.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsSeptember 2026
2 eventsShow 2 earlier months
July 2026
5 events- Alkermes expanded access with three large Medicare Part D plans.
- Norges Bank purchased a new stake in Alkermes and disclosed financial information to the SEC.
- MarketBeat is tracking analyst ratings and price targets for Alkermes stock, involving Royal Bank of Canada.
- Alkermes is developing a generic equivalent of a brand product and seeking market entry for generic drugs in partnership with Granules India Limited.
- Alkermes filed transaction disclosures with the SEC on July 1, 2026.
June 2026
17 events- Bank of America and Royal Bank of Canada raised price targets and ratings for Alkermes on June 17, 2026.
- The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.
- Director Christopher Wright sold shares of Alkermes stock, with the transaction disclosed in a legal filing with the SEC.
- FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.
- Alkermes is integrating Avadel into its operations while discussing differentiation within the orexin agonist class.
- Alkermes stock was listed on the Nasdaq exchange on June 6, 2026.
- Alkermes plc, headquartered in Ireland, plans to present findings at SLEEP 2025 in Seattle.
- Brian P. McKeon was appointed to the Board of Directors of National Veterinary Associates.
- Analysts set price targets for Alkermes stock on July 14, 2025.
- Alkermes (Q30283646) is being analyzed by Wall Street regarding how key metrics influenced its top- and bottom-line performance.
- Alkermes plc, a biopharmaceutical company, is based in Ireland.
- Alkermes plans to present research results at the World Sleep Congress in Singapore.
- Alkermes and CSL Limited are noted as stocks in the Medical-Biomedical and Genetics sector as of July 1, 2025.
- Alkermes and Takeda are developing orexin-related therapies and plan to present detailed data at a meeting on July 21, 2025.
- Alkermes reported its financial results from Dublin in July 2025.
- Alkermes underperformed the market so far this year as of July 29, 2025.
- Xoma is acquiring Mural Oncology, a company that was previously spun out of Alkermes.